06:20:22 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2023
2023-11-13 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 Årsstämma 2023
2023-03-24 Extra Bolagsstämma 2022
2023-02-16 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2023-04-03 14:22:00

Ahead of the Annual General Meeting of Qlife Holding AB on May 4, 2023, the Company's Nomination Committee announces its proposal regarding board members and chair of the board.

Qlife's Nomination Committee proposes that the Annual General Meeting elects Lars Bangsgaard as new Chairman of the Board, Lars Wegner as new Board member and re-election of Mette-Marie Harild, Mikael Persson and Thomas Warthoe. The existing board members Mette Gross, Ulrik Harrysson and John Moll have declined re-election.

Lars Bangsgaard (https://linkedin.com/in/lars-bangsgaard-188455159), born 1953, is one of the original founders of Qlife and had the CFO position up until March 2022. In his CFO position Lars was part of the executive management and worked closely with the Board of Directors. Lars has a long experience from finance positions in Volvo Denmark, Rockwool and Averhoff, and is a former auditor.

Lars Staal Wegner (https://linkedin.com/in/larswegner), born 1974, is an experienced CEO and board member in Biotech. Lars was CEO in US Nasdaq listed Evaxion Biotech until 2022 and has vast experience in Business Development and commercial expansion from Bavarian Nordic (former VP Commercial Affairs). Lars is a Medical Doctor from University of Southern Denmark and holds leadership and strategy education from IMD Lausanne and Harvard Business School.

"Lars Bangsgaard knows the company well, and is well equipped to support Qlife's management and board to ensure work progresses according to plans and requirements. Lars Staal Wegner's solid background in Business development will be a great addition to Qlife in our ongoing dialogues with potential partners in development and commercialization. The re-election of Mette-Marie, Mikael and Thomas will ensure the continuity in the strategic and operational plans initiated, and we are happy to have continued access to their expertise " Says Peter Warthoe, co-founder and Chairman of the Nomination Committee.

The Nomination Committee proposes the re-election of Thomas Warthoe, Mette-Marie Harild and Mikael Persson. Mette Gross, Ulrik Harrysson and John Moll has declined re-election.

The proposed board of directors is, regarding the Company's activities and stage of development, considered an adequate board composition in relation to qualifications, experience and background of the proposed board members. The Nomination Committee therefore considers that the proposed composition with five board members is adequate to meet the needs which the Company's operations are facing and will be facing.

The Nomination Committee's complete proposal and motivational statement will be presented in connection with the notice convening the Annual General Meeting.